FactSet Analysts Give Perspective Therapeutics Average Buy Rating

Summary

According to a FactSet survey of analysts, Perspective Therapeutics has an average rating of ‘Buy’ with an average target price of $14.11.Trading View

Impact Analysis

The event is at the company level as it pertains specifically to Perspective Therapeutics. The ‘Buy’ rating and target price increase from $13.38 to $14.11 suggest growing confidence in the company’s performance or future prospects among analysts.Trading View+ 2. Historical context shows varied analyst opinions: RBC raised its target price from $15 to $16, indicating a positive outlook, while Truist Financial lowered its target from $10 to $8 while maintaining a ‘Buy’ rating due to market dynamicsMarket Beat+ 2. These mixed signals suggest some uncertainty or risks related to broader market conditions or company-specific factors. Potential investment opportunities include considering Perspective Therapeutics for long positions, but investors should remain cautious of broader market recommendations that exclude the companyMarket Beat.